Cyclerion Therapeutics, Inc. (CYCN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cyclerion Therapeutics reported revenue of $2.1M, up 3.7% from $2.0M the year before. Net income was -$3.5M (a -170.1% net margin), or -$7.77 per diluted share. Operating margin was -239.8%. Operating activities generated -$3.3M of cash. At fiscal year end, Cyclerion Therapeutics held $10.0M in total assets against $900,000 in total liabilities, including $3.2M of cash and equivalents.
Open the full interactive Cyclerion Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Cyclerion Therapeutics Key Stats
| Share Price | $31.66 |
|---|---|
| Market Cap | $19.2M |
| Revenue YoY Growth | +3.7% |
| 52-Week Range | $7.56 – $44.66 |
| Shares Outstanding | 607,286 (basic, 2026 Q2) |
Cyclerion Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $3.9M | $1.6M | $0 | $2.0M | $2.1M |
| Operating Income | -$81.3M | -$55.2M | -$44.4M | -$13.0M | -$3.6M | -$5.0M |
| Pre-Tax Income | -$77.8M | -$51.6M | -$44.1M | -$5.3M | -$3.1M | -$3.5M |
| Income Tax | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$77.8M | -$51.6M | -$44.1M | -$5.3M | -$3.1M | -$3.5M |
| Diluted EPS | -$358.40 | -$184.80 | -$141.40 | -$15.75 | -$8.47 | -$7.77 |
Cyclerion Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $875,000 | $1.0M | $0 | $0 |
| Net Income | -$976,000 | -$799,000 | -$3.2M | -$1.8M |
| Diluted EPS | -$2.10 | -$0.25 | -$5.32 | -$2.87 |
Cyclerion Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.4M | $54.0M | $13.4M | $7.6M | $3.2M | $3.2M |
| Current Assets | $58.5M | $55.5M | $14.8M | $8.0M | $4.2M | $4.6M |
| Total Assets | $115.4M | $59.3M | $18.1M | $13.4M | $9.6M | $10.0M |
| Current Liabilities | $17.0M | $11.1M | $7.6M | $2.1M | $725,000 | $900,000 |
| Total Liabilities | $55.9M | $11.1M | $7.6M | $2.1M | $725,000 | $900,000 |
| Shareholders' Equity | $59.5M | $48.2M | $10.5M | $11.3M | $8.8M | $9.1M |
Cyclerion Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$72.5M | -$36.5M | -$40.6M | -$21.2M | -$4.3M | -$3.3M |
| Cash From Investing | $18,000 | $1.5M | $0 | $10.4M | $0 | — |
| Cash From Financing | $28.1M | $30.8M | $29,000 | $5.0M | $0 | $3.3M |
| Free Cash Flow | -$74.0M | -$36.5M | -$40.6M | — | — | — |
Figures from Cyclerion Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cyclerion Therapeutics financials page for every line item.
Cyclerion Therapeutics Company Profile
| Ticker | CYCN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001755237 |
Frequently Asked Questions
What was Cyclerion Therapeutics' revenue in fiscal 2025?
Cyclerion Therapeutics (CYCN) reported revenue of $2.1M for fiscal 2025.
What is Cyclerion Therapeutics' annual revenue history?
Cyclerion Therapeutics' annual revenue by fiscal year: 2020: $2.3M; 2021: $3.9M; 2022: $1.6M; 2023: $0; 2024: $2.0M; 2025: $2.1M.
What was Cyclerion Therapeutics' net income in fiscal 2025?
Cyclerion Therapeutics reported net income of -$3.5M for fiscal 2025.
What was Cyclerion Therapeutics' earnings per share (EPS) in fiscal 2025?
Cyclerion Therapeutics' diluted EPS was -$7.77 for fiscal 2025 (adjusted for any later stock splits).
What was Cyclerion Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cyclerion Therapeutics reported revenue of $0.
How many shares of Cyclerion Therapeutics are outstanding?
Cyclerion Therapeutics reported a weighted average of 607,286 basic shares outstanding in 2026 Q2.
What is Cyclerion Therapeutics' market cap?
Based on its latest closing price, Cyclerion Therapeutics (CYCN) has a market capitalization of about $19.2M.
When does Cyclerion Therapeutics' fiscal year end?
Cyclerion Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Cyclerion Therapeutics headquartered?
Cyclerion Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.